Abstracts tagged "SLE and hydroxychloroquine"

Abstract Number: 2990 • 2017 ACR/ARHP Annual Meeting
Is Risk of Retinopathy Among Hydroxychloroquine Users of SLE Patients Accurate? a Simulation Study Accounting for Competing Risk of Death
Na Lu¹, Hyon K. Choi², April Jorge³ and Yuqing Zhang⁴, ¹Clinical Epidemiology, Boston University School of Medicine, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴School Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Hydroxychloroquine (HCQ) is used for the long-term treatment of systemic lupus erythematosus (SLE) patients. HCQ is generally well-tolerated with wide-ranging benefits, including reduced disease…
Abstract Number: 1815 • 2015 ACR/ARHP Annual Meeting
Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence
Laura Durcan¹, William Clarke², Laurence S Magder³ and Michelle Petri¹, ¹Rheumatology, Johns Hopkins University Hospital, Baltimore, MD, ²Department of Pathology, Clinical Chemistry., Johns Hopkins University Hospital, Baltimore, MD, ³Epidemiology and Preventive Medicine, University of MD, Baltimore, MD
Background/Purpose: Hydroxychloroquine is at the cornerstone of systemic lupus erythematosus (SLE) management. It is used for both its effect on disease activity and long-term benefits.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].